International scientific guideline: Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies

About this guideline

TGA adopted date: 11 Nov 2022

Overseas effective date:  1 Nov 2016

Categories: Clinical efficacy and safety | Antineoplastic and immunomodulating agents

Access this international scientific guideline

For more information see International scientific guidelines adopted in Australia.

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.